Praxbind Injection
Product Images NDC 0597-0197

8 FDA label images from Boehringer Ingelheim Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Praxbind (NDC 0597-0197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Praxbind 01)

Figure 1 (Praxbind 01)
The image shows two clear injection vials labeled Praxbind (idarucizumab) 50 mg/mL for intravenous use. Each vial contains 50 mg of the drug in a single-dose vial. The label includes the product name, dosage form, strength, and instructions for intravenous use. The labeler is not fully visible in the image.*
FDA Label Image

Figure 2 (Praxbind 02)

Figure 2 (Praxbind 02)
An instructional diagram showing the preparation of Praxbind (idarucizumab) injection for intravenous use. It depicts a vial labeled Praxbind 5 mL and a syringe needle inserted into the vial, demonstrating the drawing up of the liquid medication into the syringe for administration.*
FDA Label Image

Figure 3 (Praxbind 03)

Figure 3 (Praxbind 03)
An illustration showing a syringe drawing liquid from a vial labeled Praxbind (idarucizumab), an injection for intravenous use. Next to it is a separate vial of Praxbind with a readable label including product and strength details.*
FDA Label Image

Figure 4 (Praxbind 04)

Figure 4 (Praxbind 04)
A line graph depicting unbound dabigatran concentrations (ng/mL) over time (hours) after the end of infusion, comparing two groups: dabigatran etexilate with idarucizumab and dabigatran etexilate with placebo. The graph includes error bars and a lower limit of quantification at 1 ng/mL. An inset graph zooms in on the first 2 hours post-infusion.*
FDA Label Image

Figure 5 (Praxbind 05)

Figure 5 (Praxbind 05)
A line graph showing Ecarin Clotting Time (ECT) in seconds over time after the end of infusion in hours. It compares two groups: one receiving Dabigatran etexilate plus Idarucizumab, and the other Dabigatran etexilate plus Placebo. The graph includes an upper limit normal threshold line and an inset zooms in on the time period around infusion end (0 hours). Error bars indicate variability in measurements at each time point.*
FDA Label Image

Figure 6 (Praxbind 06)

Figure 6 (Praxbind 06)
A box plot chart displaying ECT (sec) values on the y-axis versus time post Idarucizumab on the x-axis, showing measurements at baseline, between 10-30 minutes, and at 1, 2, 4, 12, and 24 hours after administration. The chart includes individual data with median and interquartile ranges, with markers for 5th/95th percentiles, and a dashed line representing the upper limit of normal ECT values.*
FDA Label Image

Figure 7 (Praxbind 07)

Figure 7 (Praxbind 07)
A box-and-whisker plot illustrating activated partial thromboplastin time (aPTT) in seconds at various time points post administration of idarucizumab. The x-axis lists time intervals from baseline to 24 hours, and the y-axis shows aPTT values. The chart includes median, percentiles, and normal upper limit reference for aPTT.*
FDA Label Image

Principal Display Panel (50 mL Vial Label)

Principal Display Panel (50 mL Vial Label)
Praxbind (idarucizumab) Injection 2.5 g/50 mL (50 mg/mL) intravenous injection label. The label indicates use for intravenous use only, instructs to discard unused portions, and highlights administering 2 vials for a complete 5 g dose. The packaging shows a 50 mL single-dose vial by Boehringer Ingelheim Pharmaceuticals, Inc., including storage instructions and formulation components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.